减少最大范围的眼睛运动及其对急性Levodopa挑战的反应在帕金森病中
Juan Li1, Yuewen Li1, Xianzhou Chu1
1Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Frontiers in aging neuroscience
|April 4, 2024
概括
在帕金森病 (PD) 中,耳机运动范围减少,并且在使用利沃多巴时得到改善. 向上的视线范围有效地区分了PD,渐进性超核性麻 (PSP) 和多重系统缩 (MSA).
科学领域:
- 神经学 神经学
- 眼科医生 眼科 眼科
- 运动障碍 运动障碍
背景情况:
- 渐进性超核性麻 (PSP) 的特征是视力垂直运动受到限制.
- 眼运动功能障碍在帕金森病 (PD) 中越来越多地被认可,但最大幅度仍然没有量化.
- 与非典型帕金森症相比,在PD中缺乏对眼运动范围和利沃多巴反应的定量评估.
研究的目的:
- 量化评估帕金森病 (PD) 患者的最大眼运动范围.
- 为了评估勒沃多巴对PD眼运动范围的影响.
- 将PD中的眼运动发现与非典型帕金森症的发现进行比较,特别是渐进性超核性麻 (PSP) 和多重系统缩 (MSA).
主要方法:
- 招募了159名健康对照 (HC),154名PD,30名PSP和16名MSA患者.
- 评估垂直和水平的眼运动范围,使用适应周边的动力装置.
- 在勒沃多巴挑战后重新评估参数,并对不同组的发现进行了比较.
主要成果:
- 与HC相比,PD患者的最大眼运动范围减少.
- 利沃多巴改善了PD患者的各个方向的眼运动范围,向上视线的改善与运动症状的改善相关.
- 在PSP和MSA中,眼运动范围显著受到限制,利沃多巴效应不那么明显;向上的目光范围对区分PD,PSP和MSA最敏感.
结论:
- 减少最大眼运动范围在PD显著改善与利沃多巴治疗.
- 利沃多巴对向上视角范围的积极影响有助于区分PD与PSP和MSA.
- 定量眼运动评估,特别是向上注视,为运动障碍提供了宝贵的诊断见解.
更多相关视频
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
3.8K
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
